China remains one of the largest markets for pharmaceutical industries in the world. The China Government has been supporting research and development initiatives by various pharmaceutical companies with special attention to the biotechnology sector. The WHO has launched the Integrated Chronic Disease Prevention and Control Programme (ICP), which is one of the leading technical programmes within the Department of Chronic Diseases and Health Promotion (CHP). Such initiatives are expected to support the overall expansion of the market